Observational, open-label, non-randomized study on the efficacy of onabotulinumtoxinA in the treatment of nummular headache: The pre-numabot study.

David Garcia Azorin Javier Trigo LópezÁlvaro SierraLaura Blanco-GarcíaEnrique Martínez-PíasBlanca MartínezBlanca TalaveraÁngel L Guerrero

Published in: Cephalalgia : an international journal of headache (2019)

It was found that after injecting onabotulinumtoxinA, the number of headache days per month was reduced in nummular headache patients. The number of intense headache days per month and acute treatment days were also lowered. No serious adverse events occurred during treatment.

Keyphrases

open label
end stage renal disease
chronic kidney disease
newly diagnosed
clinical trial
randomized controlled trial
study protocol
patient reported outcomes
locally advanced